New Insider Denny Chu Joins NovaBridge Biosciences
| Field | Detail |
|---|---|
| Company | Chu Denny Hsueh Wen |
| Form Type | 3 |
| Filed Date | Mar 25, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-filing, form-3, new-insider, corporate-governance
TL;DR
**New insider Denny Chu just joined NovaBridge Biosciences, signaling potential positive changes ahead.**
AI Summary
Denny Hsueh Wen Chu, a new insider at NovaBridge Biosciences (CIK: 0001778016), filed a Form 3 on March 24, 2026, indicating their initial beneficial ownership of securities as of March 18, 2026. This filing is crucial because it signals that a new individual, likely with significant influence or knowledge, has joined the company's ranks, which can be a positive indicator for future performance and strategic direction for investors considering NovaBridge Biosciences stock.
Why It Matters
A new insider joining NovaBridge Biosciences could bring fresh perspectives and expertise, potentially leading to new strategies or improved performance, which can positively impact the stock's value.
Risk Assessment
Risk Level: low — This filing is a standard disclosure for new insiders and does not inherently present a direct financial risk.
Analyst Insight
Investors should monitor future filings from Denny Hsueh Wen Chu (Forms 4 and 5) to understand their trading activity and any potential changes in NovaBridge Biosciences' strategy or performance.
Key Players & Entities
- Chu Denny Hsueh Wen (person) — Reporting Person
- NovaBridge Biosciences (company) — Issuer
- 0002123744 (person) — CIK of Reporting Person
- 0001778016 (company) — CIK of Issuer
Forward-Looking Statements
- Denny Hsueh Wen Chu will play a significant role in NovaBridge Biosciences' strategic direction. (NovaBridge Biosciences) — medium confidence, target: 2027-03-24
FAQ
Who is the reporting person in this Form 3 filing?
The reporting person is Chu Denny Hsueh Wen, identified by CIK 0002123744.
What company is the issuer of the securities in this filing?
The issuer is NovaBridge Biosciences, identified by CIK 0001778016, with a business address at SUITE 400, 2440 RESEARCH BLVD, ROCKVILLE MD 20850.
What is the filing date of this Form 3?
The filing date for this Form 3 is March 24, 2026, and it was accepted on the same date at 20:08:23.
What is the period of report for this filing?
The period of report for this filing is March 18, 2026.
What type of business is NovaBridge Biosciences according to its SIC code?
NovaBridge Biosciences is classified under SIC 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 425 words · 2 min read · ~1 pages · Grade level 9.2 · Accepted 2026-03-24 20:08:23
Filing Documents
- ownership.html (3)
- ownership.xml (3) — 2KB
- ck0001778016-ex24_1.htm (EX-24.1) — 21KB
- 0001193125-26-122444.txt ( ) — 24KB
From the Filing
SEC FORM 3 SEC Form 3 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5 1. Name and Address of Reporting Person * Chu Denny Hsueh Wen (Last) (First) (Middle) C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400 (Street) ROCKVILLE MARYLAND 20850 (City) (State) (Zip) UNITED STATES (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026 3. Issuer Name and Ticker or Trading Symbol NovaBridge Biosciences [ NBP ] 3a. Foreign Trading Symbol 5. If Amendment, Date of Original Filed (Month/Day/Year) 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) See Remarks 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: Remarks: EVP, Head of Strategic Partnership Exhibit List: Ex. 24.1 - Power of Attorney No securities are beneficially owned. /s/ Xi-Yong (Sean) Fu as attorney-in-fact 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26)